<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09943R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007250</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Physiology/Endocrinology</subject><subject>Diabetes and Endocrinology/Endocrinology</subject><subject>Diabetes and Endocrinology/Obesity</subject></subj-group></article-categories><title-group><article-title>12/15-Lipoxygenase Is Required for the Early Onset of High Fat Diet-Induced Adipose Tissue Inflammation and Insulin Resistance in Mice</article-title><alt-title alt-title-type="running-head">Insulin Resistance and 12/15LO</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sears</surname><given-names>Dorothy D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miles</surname><given-names>Philip D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chapman</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ofrecio</surname><given-names>Jachelle M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Almazan</surname><given-names>Felicidad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thapar</surname><given-names>Divya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Yury I.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, California, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Pfizer Inc., La Jolla, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Maedler</surname><given-names>Kathrin</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Bremen, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>dsears@ucsd.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: DDS YM. Performed the experiments: DDS PDM JC JMO FA DT YM. Analyzed the data: DDS PDM JC DT YM. Contributed reagents/materials/analysis tools: DDS PDM JC YM. Wrote the paper: DDS PDM YM.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>9</month><year>2009</year></pub-date><volume>4</volume><issue>9</issue><elocation-id>e7250</elocation-id><history><date date-type="received"><day>23</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Sears et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Recent understanding that insulin resistance is an inflammatory condition necessitates searching for genes that regulate inflammation in insulin sensitive tissues. 12/15-lipoxygenase (12/15LO) regulates the expression of proinflammatory cytokines and chemokines and is implicated in the early development of diet-induced atherosclerosis. Thus, we tested the hypothesis that 12/15LO is involved in the onset of high fat diet (HFD)-induced insulin resistance.</p></sec><sec><title>Methodology/Principal Findings</title><p>Cells over-expressing 12/15LO secreted two potent chemokines, MCP-1 and osteopontin, implicated in the development of insulin resistance. We assessed adipose tissue inflammation and whole body insulin resistance in wild type (WT) and 12/15LO knockout (KO) mice after 2&#x02013;4 weeks on HFD. In adipose tissue from WT mice, HFD resulted in recruitment of CD11b<sup>&#x0002b;</sup>, F4/80<sup>&#x0002b;</sup> macrophages and elevated protein levels of the inflammatory markers IL-1&#x003b2;, IL-6, IL-10, IL-12, IFN&#x003b3;, Cxcl1 and TNF&#x003b1;. Remarkably, adipose tissue from HFD-fed 12/15LO KO mice was not infiltrated by macrophages and did not display any increase in the inflammatory markers compared to adipose tissue from normal chow-fed mice. WT mice developed severe whole body (hepatic and skeletal muscle) insulin resistance after HFD, as measured by hyperinsulinemic euglycemic clamp. In contrast, 12/15LO KO mice exhibited no HFD-induced change in insulin-stimulated glucose disposal rate or hepatic glucose output during clamp studies. Insulin-stimulated Akt phosphorylation in muscle tissue from HFD-fed mice was significantly greater in 12/15LO KO mice than in WT mice.</p></sec><sec><title>Conclusions</title><p>These results demonstrate that 12/15LO mediates early stages of adipose tissue inflammation and whole body insulin resistance induced by high fat feeding.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Insulin resistance is a pathophysiological condition associated with obesity, aging, and type 2 diabetes that affects skeletal muscle, liver, adipose tissue, and immune cells. Obesity and insulin resistance are associated with macrophage infiltration and inflammation in the adipose tissue of humans and rodent models where a feed-forward cycle of reciprocal adipocyte and macrophage activation results in the secretion of inflammatory proteins and further macrophage recruitment <xref ref-type="bibr" rid="pone.0007250-deLuca1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Matsuzawa1">&#x0005b;2&#x0005d;</xref>. Pro-inflammatory factors secreted by macrophages and adipocytes are elevated in adipose tissue from obese and type 2 diabetic patients <xref ref-type="bibr" rid="pone.0007250-Hotamisligil1">&#x0005b;3&#x0005d;</xref>. Adipose tissue inflammation induces insulin resistance through inactivation of insulin receptor substrates (IRS) by cytokine-activated JNK, IKK&#x003b2; and SOCS <xref ref-type="bibr" rid="pone.0007250-deLuca1">&#x0005b;1&#x0005d;</xref>. High fat diet (HFD) feeding, a commonly studied model of insulin resistance in rodents, rapidly causes progressive metabolic maladies <xref ref-type="bibr" rid="pone.0007250-Park1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Strissel1">&#x0005b;5&#x0005d;</xref>. Insulin resistance in heart, adipose tissue, liver, and muscle, adipose tissue hypertrophy and inflammatory cell infiltration, and hyperinsulinemia are significantly robust phenotypes observed as early as 1&#x02013;3 weeks of HFD, with minimal to no total body weight gain <xref ref-type="bibr" rid="pone.0007250-Park1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Nguyen1">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Kraegen1">&#x0005b;8&#x0005d;</xref>. After 16&#x02013;20 weeks of HFD, these phenotypes are much more pronounced and additional severe metabolic dysregulations are present including dyslipidemia &#x00026; ectopic triglyceride storage, hypo-adiponectinemia, adipose tissue hypoxia, cell death and remodeling, beta-cell decompensation, mild hyperglycemia, and deterioration of cardiac function <xref ref-type="bibr" rid="pone.0007250-Park1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Nguyen1">&#x0005b;6&#x0005d;</xref>. The key molecules involved in initiating HFD-induced adipose tissue inflammation and macrophage infiltration are not well characterized. Recent studies suggest an important role for 12/15-lipoxygenase (12/15LO) in monocyte recruitment to and regulation of inflammation in vascular and adipose tissue.</p><p>The family of 12/15LO enzymes catalyzes the insertion of molecular oxygen in arachidonic acid (20&#x02236;4) at the 12<sup>th</sup> and/or 15<sup>th</sup> carbon, resulting in a fatty acid hydroperoxide. 12/15LO oxygenates linoleic acid (18&#x02236;2) at the 9<sup>th</sup> and/or 13<sup>th</sup> carbon. Free unsaturated fatty acids as well as fatty acids esterified in phospholipids and cholesteryl esters are substrates for 12/15LO. The 12/15LO enzymes are conserved among many plant and animal species and include soybean 15LO, human 15LO (Entrez Gene ID 246), and mouse 12/15LO (Entrez Gene ID 11687). In mammals, 12/15LO is expressed in differentiated macrophages, dendritic cells, inflamed endothelial and smooth muscle cells, and in certain tumors <xref ref-type="bibr" rid="pone.0007250-Natarajan1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Pidgeon1">&#x0005b;14&#x0005d;</xref>. There is an emerging understanding that, in both plants and mammals, 12/15LO products are involved in the signaling processes of defense response and inflammation. In plants, 12/15LO initiates the synthesis of jasmonic acid, which regulates defensive genes that respond to wound- and insect-inflicted damage <xref ref-type="bibr" rid="pone.0007250-Browse1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Delker1">&#x0005b;16&#x0005d;</xref>. In mammalian cells, 12/15LO products regulate small GTPases Ras and RhoA, MAP kinases, PKC, and transcription factor NF-&#x003ba;B <xref ref-type="bibr" rid="pone.0007250-Bolick1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Natarajan2">&#x0005b;17&#x0005d;</xref>. Our previous studies suggest that 12/15LO oxidation products activate toll-like receptor-4 (TLR4) in macrophages <xref ref-type="bibr" rid="pone.0007250-Miller1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Miller2">&#x0005b;19&#x0005d;</xref>. Cells that express 12/15LO or are activated with 12/15LO oxidation products produce MCP-1, IL-6, IL-8 and TNF&#x003b1; and induce monocyte binding to endothelial cells <xref ref-type="bibr" rid="pone.0007250-Dwarakanath1">&#x0005b;20&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Wen2">&#x0005b;26&#x0005d;</xref>.</p><p>12/15LO has been implicated in the development of autoimmune diabetes and in vascular complications of diabetes. Arachidonic acid stimulates insulin secretion by &#x003b2;-cells and this process is inhibited by the 12/15LO activity <xref ref-type="bibr" rid="pone.0007250-Persaud1">&#x0005b;27&#x0005d;</xref>. Moreover, 12/15LO mediates cytokine-induced &#x003b2;-cell damage <xref ref-type="bibr" rid="pone.0007250-Chen1">&#x0005b;28&#x0005d;</xref>. Other data suggest that non-obese diabetic (NOD) mice congenic for a targeted deletion of 12/15LO are in fact protected from autoimmune diabetes <xref ref-type="bibr" rid="pone.0007250-McDuffie1">&#x0005b;29&#x0005d;</xref>. A recent study has shown that long-term (8&#x02013;24 weeks) high fat feeding induces 12/15LO activation and beta cell damage in pancreatic islets, both of which were prevented in 12/15LO KO mice <xref ref-type="bibr" rid="pone.0007250-Nunemaker1">&#x0005b;30&#x0005d;</xref>. 12/15LO is also involved in vascular complications of advanced diabetes, such as atherosclerosis and nephropathy, which manifest life-threatening conditions. Specifically under diabetic conditions, vascular smooth muscle cells (VSMC) express 12/15LO which in turn mediates a VSMC switch from a contractile phenotype to a migratory and inflammatory phenotype <xref ref-type="bibr" rid="pone.0007250-Natarajan1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Dwarakanath2">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Natarajan4">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Li2">&#x0005b;32&#x0005d;</xref>. This change together with 12/15LO-mediated lipoprotein oxidation and monocyte adhesion to endothelial cells explains the involvement of 12/15LO in the pathogenesis of high fat diet (HFD)-induced atherosclerosis <xref ref-type="bibr" rid="pone.0007250-Cyrus1">&#x0005b;33&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Bolick2">&#x0005b;36&#x0005d;</xref>.</p><p>Although these previous studies show that 12/15LO plays a role in regulating &#x003b2;-cell survival, advanced diabetic complications and, in a very recent publication, chronic (8&#x02013;24 weeks) HFD-induced insulin resistance and inflammation <xref ref-type="bibr" rid="pone.0007250-Nunemaker1">&#x0005b;30&#x0005d;</xref>, the possible involvement of 12/15LO in the early development of insulin resistance has not been studied. Given that 12/15LO is an inflammatory modulator, we asked whether it is required for the onset of HFD-induced insulin resistance. We found that 12/15LO deficiency protected mice from exhibiting elevated inflammatory markers in adipose tissue and, remarkably, prevented whole-body insulin resistance induced by 2&#x02013;4 weeks of high fat feeding.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Cells</title><p>Murine fibroblast cell lines stably over-expressing human 15LO or &#x003b2;-galactosidase (LacZ) <xref ref-type="bibr" rid="pone.0007250-Benz1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Ezaki1">&#x0005b;38&#x0005d;</xref> were cultured in 10&#x00025; FBS/DMEM/gentamicin with 0.5 mg/ml G418 (Calbiochem, San Diego, CA) to maintain selection.</p></sec><sec id="s2b"><title>Animals</title><p>Male C57BL6 wild type mice were from Jackson Laboratories. Male 12/15LO knockout mice, backcrossed in a C57BL6 background for 10 generations, were a generous gift from Dr. Colin Funk (Queen's University). Starting 16 weeks of age, mice were fed either normal chow (12&#x00025; kcal from fat; Purina 5001 Lab Diet) of high fat diet (41&#x00025; kcal from fat; TD96132, Harlan Teklad) for 2 or 4 weeks. All mice involved in clamp studies (wild type and 12/15LO KO, n&#x0200a;&#x0003d;&#x0200a;20 each) were singly housed during the two weeks of dietary intervention. This was done in order to ensure equal food access, protect the implanted catheters, and prevent fighting between mice. Mice used for other experiments (acute insulin and adipose tissue FACS studies, n&#x0200a;&#x0003d;&#x0200a;20 per strain) were housed 1&#x02013;3 in a cage. There were infrequent circumstances (&#x0223c;5 mice total in these studies) when a non-clamp study mouse was singly-housed (for example, an aggressor had to be separated from cage mates to prevent stress and injury to the other mice and to ensure access to food. Mice were housed under controlled light (12&#x02236;12 light&#x02236;dark) and climate conditions with unlimited access to food and water. All procedures were performed in accordance with the <italic>Guide for Care and Use of Laboratory Animals</italic> of the National Institutes of Health and were approved by the University of California, San Diego, Animal Subjects Committee.</p></sec><sec id="s2c"><title>Analytical methods</title><p>Total RNA was isolated from cell lysates using an RNeasy kit from Quiagen (Valencia, CA). Quantitative RT-PCR was performed to measure MCP-1, OPN and GAPDH mRNA levels using a Rotor-Gene RG3000 qPCR machine (Corbett Research, Brisbane, Australia). Primers and probes were from Applied Biosystems (Foster City, CA). The protein levels of MCP-1 in conditioned media were measured by ELISA using a kit from R&#x00026;D Systems (Minneapolis, MN). The protein levels of OPN in conditioned media were assayed by immunoblot using a primary antibody from Santa Cruz Biotechnology (Santa Cruz, CA).</p></sec><sec id="s2d"><title>In vivo metabolic studies</title><p>Insulin sensitivity was assessed in mice fed HFD for 2 weeks using a sub-maximal hyperinsulinemic euglycemic glucose clamp technique as previously described (34), with the following modifications: 1) isoflurane was used for anesthesia during the catheter insertion surgery three days prior to clamp, 2) glucose tracer was infused at 2 &#x003bc;Ci/hr during the clamp, and 3) insulin was infused at 3 mU/kg/min during the clamp. The mice were conscious during the clamp and fully recovered after the procedure. Four days later, the mice were fasted for 5 hr, anesthetized (isoflurane) to collect blood by cardiac puncture, and then euthanized (pentobarbital) to collect gastrocnemius muscle, liver, and epididymal adipose tissues. Excised tissues were flash-frozen in liquid nitrogen. Plasma glucose specific activity, glucose disposal rate (GDR), and hepatic glucose output (HGO) were calculated as previously described <xref ref-type="bibr" rid="pone.0007250-Miles1">&#x0005b;39&#x0005d;</xref>. In a separate group of mice, acute insulin stimulation was achieved by intraperitoneal injection of 6 hr-fasted mice with 0.85 U/kg insulin. After 15 min, the mice were sacrificed and muscle was harvested as described above.</p></sec><sec id="s2e"><title>Fluorescence-activated cell sorting (FACS) of adipose tissue SVCs</title><p>Adipose tissue stromal vascular cells (SVCs) were isolated and analyzed by FACS as previously reported <xref ref-type="bibr" rid="pone.0007250-Nguyen1">&#x0005b;6&#x0005d;</xref> with minor modifications. Briefly, freshly harvested epididymal fat pads were separately rinsed and minced in DPBS &#x0002b;1&#x00025; BSA and then treated with 1 mg/mL type II collagenase (Sigma, St. Louis, MO) for 25 min in a 37&#x000b0;C shaking water bath. Adipose tissue cell suspensions were filtered through a 100 &#x000b5;m mesh. SVCs were separated from floating adipocytes by centrifugation, incubated in RBC lysis buffer (eBioscience, San Diego, CA) for 5 min, and re-suspended in fresh DPBS &#x0002b;1&#x00025; BSA. SVCs were incubated with Fc Block (BD Biosciences, San Jose, CA) for 15 min and then stained for 30 min with fluorescent-conjugated antibodies against F4/80 (Ab Serotec, Raleigh, NC) and CD11b (BD Biosciences). Cells were washed two times and re-suspended in DPBS &#x0002b;1&#x00025; BSA and propidium iodide (Sigma). Presence of the fluorescent stains in the SVCs was analyzed using a FACS Calibur flow cytometer (BD Biosciences). Control SVCs preparations included unstained cells, PI-only stained cells, and fluorescence-minus-one (FMO) stained cells and were used to set gatings and compensation.</p></sec><sec id="s2f"><title>Plasma and tissue analyses</title><p>Plasma insulin levels were measured using the Insulin Ultrasensitive (Mouse) EIA method (Alpco, Salem, NH). Muscle lysates were analyzed by western blotting with antibodies against total Akt and phospho-serine Akt (Cell Signaling, Danvers, MA). Signal intensities on chemiluminescence-exposed autoradiographs were densitometrically quantified using a digital Kodak 3D Image station and associated digital image analysis software (Kodak, New Haven, CT). The protein levels of IL-1&#x003b2;, IL-12p70, IFN&#x003b3;, IL-6, IL-10, Cxcl1 and TNF&#x003b1; in adipose tissue lysates were measured using a multiplex (7-plex) ELISA (Meso Scale Discovery, Gaithersburg, MD).</p></sec><sec id="s2g"><title>Statistical analyses</title><p>Student's t-test and ANOVA (and Tukey's post hoc test) were applied for statistical analyses. A p-value cutoff of 0.05 was used to determine statistical significance.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>12/15LO expression increases chemokine production</title><p>Expression of 12/15LO in various smooth muscle cells and macrophages induces the expression of proinflammatory genes <xref ref-type="bibr" rid="pone.0007250-Li1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Dwarakanath2">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Wen1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Wen2">&#x0005b;26&#x0005d;</xref>. We used fibroblast cell lines that stably express human 15LO or LacZ (as a negative control) <xref ref-type="bibr" rid="pone.0007250-Benz1">&#x0005b;37&#x0005d;</xref> to test whether our 15LO-expressing cells (15LO cells) produce excess pro-inflammatory proteins compared to LacZ-expressing control cells (LacZ cells). We focused on chemokines that could attract monocytes to adipose tissue and have been shown to be involved in the pathogenesis of insulin resistance. Monocyte chemoattractant protein-1 (MCP-1) contributes to macrophage infiltration in adipose tissue and insulin resistance <xref ref-type="bibr" rid="pone.0007250-Kanda1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Kamei1">&#x0005b;41&#x0005d;</xref>. Osteopontin (OPN) is a proinflammatory cytokine and monocyte chemotactic factor that also mediates obesity-induced insulin resistance <xref ref-type="bibr" rid="pone.0007250-Nomiyama1">&#x0005b;42&#x0005d;</xref>. We found that the 15LO cells expressed significantly higher levels of MCP-1 and OPN (mRNA and protein) than the LacZ cells (<xref ref-type="fig" rid="pone-0007250-g001">Figure 1</xref>). Expression of other inflammatory mediators TNF&#x003b1;, MIP-2, MIP-1&#x003b1; and I&#x003ba;B&#x003b6; was not different between the 15LO and LacZ cells (not shown).</p><fig id="pone-0007250-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.g001</object-id><label>Figure 1</label><caption><title>Proinflammatory chemokine production by 15LO-expressing cells.</title><p>A. Fold difference in OPN and MCP-1 mRNA expression in murine fibroblasts constitutively expressing human 15LO or LacZ. OPN and MCP-1 mRNA levels were measured by qPCR of total RNA and were normalized to GAPDH mRNA. B. Levels of MCP-1 protein in conditioned media from 15LO and LacZ cells, as assayed by ELISA. C. Autoradiograph of OPN protein in conditioned media from 15LO and LacZ cells, as determined by western blotting.</p></caption><graphic xlink:href="pone.0007250.g001"/></fig></sec><sec id="s3b"><title>HFD-induced inflammation in adipose tissue is absent in 12/15LO KO mice</title><p>Because 12/15LO regulates the expression of monocytic chemokines (<xref ref-type="fig" rid="pone-0007250-g001">Figure 1</xref> and refs. <xref ref-type="bibr" rid="pone.0007250-Li1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Dwarakanath2">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Wen1">&#x0005b;24&#x0005d;</xref>), we compared the effects of short-term high fat feeding on adipose tissue inflammation in C57BL6 wild type (WT) and strain-, gender-, and age-matched 12/15LO knockout (KO) mice. We assessed adipose tissue macrophage infiltration in isolated epididymal white adipose tissue-derived stromal vascular cells (SVCs) using fluorescence-activated cell sorting (FACS), which is a more sensitive and comprehensive method compared to immuno-histochemistry. Because macrophages expressing F4/80 and/or CD11b are increased in adipose tissue after HFD <xref ref-type="bibr" rid="pone.0007250-Strissel1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Kanda1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Weisberg1">&#x0005b;43&#x0005d;</xref>, we measured the percentage of live SVCs that express F4/80 or CD11b and the percentage of live SVCs that express both F4/80 and CD11b. The percentage of adipose tissue-derived SVCs expressing F4/80 and/or CD11b was significantly increased in WT mice fed HFD for two weeks (<xref ref-type="fig" rid="pone-0007250-g002">Figure 2</xref>) compared to WT mice fed normal chow (NC). This trend of increased macrophage presence also existed after four weeks of HFD. In contrast, adipose tissue-derived SVCs isolated from 12/15LO KO mice fed HFD for four weeks exhibited no change in the percentage of cells expressing F4/80 and CD11b compared with NC-fed 12/15LO KO mice.</p><fig id="pone-0007250-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.g002</object-id><label>Figure 2</label><caption><title>FACS analysis of macrophage content in adipose tissue SVCs.</title><p>A. HFD-induced fold change in the percent of live adipose tissue SVCs expressing surface markers F4/80, CD11b, and both F4/80 and CD11b. SVCs were isolated from eWAT of mice fed NC, two-week HFD, or four-week HFD. &#x0002a;p&#x0003c;0.05 vs WT NC, &#x002c6;p&#x0003c;0.05 vs WT two-week HFD, <sup>&#x00024;</sup>p&#x0003c;0.05 vs WT four-week HFD.</p></caption><graphic xlink:href="pone.0007250.g002"/></fig><p>We next measured cytokine protein levels in epididymal white adipose tissue (eWAT) lysates from WT and 12/15LO KO mice fed NC or HFD for two weeks. We observed significantly elevated levels of IL-1&#x003b2;, IL-12p70, IFN&#x003b3;, IL-6, and IL-10 in eWAT lysates from HFD-fed WT mice compared to NC-fed WT mice (<xref ref-type="fig" rid="pone-0007250-g003">Figure 3</xref>). Cxcl1 (KC) and TNF&#x003b1; levels also tended to increase after HFD in WT mice but this increase did not reach statistical significance. None of these cytokines were elevated in the plasma of WT mice fed 2-week HFD compared to NC controls. In contrast to WT mice, 12/15LO KO mice were completely protected from HFD-induced increases in IL-1&#x003b2;, IL-12p70, IFN&#x003b3;, IL-6, IL-10, Cxcl1 and TNF&#x003b1; levels in eWAT. The absence of HFD-induced cytokine elevation in the adipose tissue of 12/15LO KO mice (<xref ref-type="fig" rid="pone-0007250-g003">Figure 3</xref>) corresponds with the absence of HFD-induced macrophage infiltration in the adipose tissue of these mice (<xref ref-type="fig" rid="pone-0007250-g002">Figure 2</xref>) and supports the notion that, in contrast to WT mice, 12/15LO KO mice fed HFD for two to four weeks do not exhibit macrophage-mediated, adipose tissue inflammation.</p><fig id="pone-0007250-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.g003</object-id><label>Figure 3</label><caption><title>Adipose tissue cytokine levels.</title><p>Cytokine protein levels measured in eWAT lysates from WT (black bars) and 12/15LO KO (gray bars) mice fed NC or two-week HFD. Values are mean&#x000b1;standard error. 8&#x02013;10 animals per group. &#x0002a;p&#x0003c;0.05 vs diet-matched WT, <sup>#</sup>p&#x0003c;0.05 vs strain-matched NC.</p></caption><graphic xlink:href="pone.0007250.g003"/></fig></sec><sec id="s3c"><title>12/15LO KO mice are protected from HFD-induced insulin resistance</title><p>We investigated whether the absence of HFD-induced adipose tissue inflammation in 12/15LO KO mice correlated with protection from whole body insulin resistance. We conducted euglycemic hyperinsulinemic clamp studies on WT and 12/15LO KO mice fed NC or HFD for two weeks. High fat feeding induced significant differences in clamp data from HFD-fed compared to NC-fed WT mice, specifically, 76&#x00025; lower glucose infusion rate (Ginf), 60&#x00025; lower glucose disposal rate (GDR), and 76&#x00025; higher hepatic glucose output rate (HGO) (<xref ref-type="fig" rid="pone-0007250-g004">Figure 4A&#x02013;C</xref>). 12/15LO KO mice were completely protected from the severe HFD-induced changes in Ginf, GDR, and HGO that we observed in WT mice. There was no significant difference in basal glucose turnover rate (basal HGO&#x0200a;&#x0003d;&#x0200a;basal GDR) between the NC-fed WT (15.9&#x000b1;2.2 mg/kg/min) and 12/15LO KO mice (16.0&#x000b1;1.9 mg/kg/min) or between the WT NC-fed and WT HFD-fed mice (15.7&#x000b1;1.9 mg/kg/min). The clamp study data indicate that 12/15LO deficiency provides protection from HFD-induced hepatic and skeletal muscle insulin resistance. HFD-fed 12/15LO KO mice did exhibit a similar fold increase in eWAT mass but not hyperinsulinemia, compared to HFD-fed WT mice (<xref ref-type="table" rid="pone-0007250-t001">Table 1</xref>). To demonstrate that there was no direct dependency between adiposity and insulin resistance in WT and 12/15LO KO mice, we normalized the GDR values to the fat pad mass as a &#x00025; of body weight. <xref ref-type="fig" rid="pone-0007250-g004">Figure 4D</xref> shows that, even after this normalization, there remains a dramatically different insulin sensitivity between WT and 12/15LO KO mice fed chow or high-fat diet.</p><fig id="pone-0007250-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.g004</object-id><label>Figure 4</label><caption><title>Characterization of whole body insulin sensitivity.</title><p>Hyperinsulinemic euglycemic clamp studies were conducted to calculate (A) Ginf, (B) GDR, (C) HGO, and (D) GDR normalized to fat pad mass as a percent of body weight in WT (black bars) and 12/15LO KO (gray bars) mice fed NC or two-week HFD. Values are mean&#x000b1;standard error. 7&#x02013;9 animals per group. &#x0002a;p&#x0003c;0.05 vs WT HFD, <sup>#</sup>p&#x0003c;0.05 vs WT NC.</p></caption><graphic xlink:href="pone.0007250.g004"/></fig><table-wrap id="pone-0007250-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.t001</object-id><label>Table 1</label><caption><title>Mouse strain characteristics.</title></caption><alternatives><graphic id="pone-0007250-t001-1" xlink:href="pone.0007250.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">WT</td><td colspan="3" align="left" rowspan="1">12/15-LO KO</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NC</td><td align="left" rowspan="1" colspan="1">HFD</td><td align="left" rowspan="1" colspan="1">Fold Change</td><td align="left" rowspan="1" colspan="1">NC</td><td align="left" rowspan="1" colspan="1">HFD</td><td align="left" rowspan="1" colspan="1">Fold Change</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Whole body weight, g</bold></td><td align="left" rowspan="1" colspan="1">26.4 (0.5)</td><td align="left" rowspan="1" colspan="1">31.2 (0.7) <bold>#</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25.2 (0.9)</td><td align="left" rowspan="1" colspan="1">25.2 (0.8) &#x0002a;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Epididymal fat pad weight, g</bold></td><td align="left" rowspan="1" colspan="1">0.32 (0.02)</td><td align="left" rowspan="1" colspan="1">0.78 (0.06) <bold>#</bold></td><td align="left" rowspan="1" colspan="1">2.45 (0.20)</td><td align="left" rowspan="1" colspan="1">0.23 (0.01)</td><td align="left" rowspan="1" colspan="1">0.43 (0.06) #, &#x0002a;</td><td align="left" rowspan="1" colspan="1">1.89 (0.26), <bold>ns vs WT HFD</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Epididymal fat pad mass, &#x00025; body weight</bold></td><td align="left" rowspan="1" colspan="1">1.20 (0.08)</td><td align="left" rowspan="1" colspan="1">2.49 (0.19) #</td><td align="left" rowspan="1" colspan="1">2.07 (0.16)</td><td align="left" rowspan="1" colspan="1">0.89 (0.04)</td><td align="left" rowspan="1" colspan="1">1.64 (0.18) #, &#x0002a;</td><td align="left" rowspan="1" colspan="1">1.84 (0.20), <bold>ns vs WT HFD</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fasting plasma glucose, mg/dL</bold></td><td align="left" rowspan="1" colspan="1">160 (5)</td><td align="left" rowspan="1" colspan="1">174 (6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">177 (5)</td><td align="left" rowspan="1" colspan="1">202 (9) #, &#x0002a;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fasting plasma insulin, ng/mL</bold></td><td align="left" rowspan="1" colspan="1">0.51 (0.18)</td><td align="left" rowspan="1" colspan="1">2.28 (0.83) #</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.63 (0.22)</td><td align="left" rowspan="1" colspan="1">0.57 (0.18) &#x0002a;</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><p>Data are averages&#x000b1;standard error. 7&#x02013;10 mice per group. &#x0002a; p&#x0003c;0.05 vs diet-matched WT, # p&#x0003c;0.05 vs strain-matched NC. ns - not significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Diminished insulin-activated Akt phosphorylation in muscle from HFD-fed WT compared to 12/15LO KO mice</title><p>In order to assess the effects of 12/15LO KO on insulin signal transduction in skeletal muscle from mice fed HFD, we examined acute insulin-activated Akt phosphorylation in a separate group of mice. Serine-phosphorylation of Akt in muscle lysates (phospho-Ser<sup>473</sup> Akt normalized to total Akt protein) was determined by western blot using primary antibodies for total Akt protein and phospho-Ser<sup>473</sup> Akt. As expected, acute insulin treatment induced phosphorylation of Akt in both groups (<xref ref-type="fig" rid="pone-0007250-g005">Figure 5</xref>). However, the absolute level of insulin-stimulated Akt phosphorylation and the insulin-stimulated fold change in Akt phosphorylation were both significantly greater, two- and three-fold, respectively, in 12/15LO KO mice compared to WT mice. Because activation (phosphorylation) of Akt is a critical early event in the insulin receptor signaling, these data corroborate our <italic>in vivo</italic> results (<xref ref-type="fig" rid="pone-0007250-g004">Figure 4B</xref>) demonstrating greater insulin sensitivity in the muscle of HFD-fed 12/15LO KO mice compared to WT mice.</p><fig id="pone-0007250-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007250.g005</object-id><label>Figure 5</label><caption><title>Basal and insulin-stimulated Akt phosphorylation in muscle of HFD-fed mice.</title><p>WT (black bars) and 12/15LO KO (gray bars) mice were fed HFD for two weeks. Mice were then injected intraperitoneally with 0.85 U/kg insulin or vehicle. After 15 min, mice were sacrificed and gastrocnemius muscles were rapidly isolated. Phospho-Ser<sup>473</sup> Akt and total Akt levels in muscle lysates were measured by western blotting. A. Representative western blot images. B. Quantitation of all Akt western blot images. Phospho-Ser<sup>473</sup> Akt/total Akt ratio values were normalized to the maximal signal observed. Bar graph values are mean&#x000b1;standard error. Insulin-induced fold changes in Akt phosphorylation are shown within the bars. 2&#x02013;6 animals per group. &#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0007250.g005"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>HFD-induced and obesity-related insulin resistance is associated with chronic low grade inflammation in adipose tissue characterized by macrophage infiltration and elevation of inflammatory cytokine expression. HFD-induced effects on adipose tissue inflammation are initiated early in the course of high fat feeding and are coincident with insulin resistance <xref ref-type="bibr" rid="pone.0007250-Strissel1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Nguyen1">&#x0005b;6&#x0005d;</xref>. Although the known biological roles of 12/15LO include regulating inflammation, a role for 12/15LO in the early development of HFD-induced adipose tissue inflammation and/or whole body insulin resistance has not been described. 12/15LO is expressed in all vascular cell types, including endothelial cells, macrophages and VSMCs, and its expression is elevated under inflammatory conditions. Therefore, we hypothesized that 12/15LO might regulate HFD-induced adipose tissue inflammation. Indeed, we found that high fat feeding induced macrophage infiltration into adipose tissue of WT but not 12/15LO KO mice, presumably, via 12/15LO-regulated chemokine secretion. The difference in adipose tissue macrophage infiltration between HFD-fed WT and 12/15LO KO mice corresponded with their difference in adipose tissue inflammatory cytokine elevation. In addition to being protected from adipose tissue inflammation, HFD-fed 12/15LO KO mice were also dramatically protected from hepatic and skeletal muscle insulin resistance compared to HFD-fed WT mice.</p><p>Adipose tissue macrophages are derived from circulating monocytes that attach to and migrate through endothelial cells (ECs) in the tissue microvasculature. 12/15LO expression and activity is increased in atherogenic and hyperglycemic diabetes models <xref ref-type="bibr" rid="pone.0007250-Bolick1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Bolick2">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Patricia1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Hatley1">&#x0005b;45&#x0005d;</xref>, conditions similar to the postprandial state of non-diabetic, diet-induced insulin resistance in which case hyperlipidemia and hyperglycemia are more pronounced and sustained. In these model conditions, activated 12/15LO regulates monocyte attachment to ECs in part by increasing expression of adhesion molecule ICAM-1 on the surface of ECs via activation of RhoA and NF-&#x003ba;B <xref ref-type="bibr" rid="pone.0007250-Bolick1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Bolick2">&#x0005b;36&#x0005d;</xref>. 12/15LO increases the expression of chemokines MCP-1 and OPN (our data presented here and <xref ref-type="bibr" rid="pone.0007250-Li1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Wen1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Wen2">&#x0005b;26&#x0005d;</xref>). Thus, 12/15LO-mediated regulation of chemoattractants and an adhesion receptor may account for the increased monocyte infiltration into adipose tissue that we observed in HFD-fed WT but not 12/15LO KO mice.</p><p>Both WT and 12/15LO KO mice exhibited an approximate two-fold increase in eWAT mass during the two-week high fat feeding period. Although HFD-induced eWAT expansion in 12/15LO KO mice was somewhat blunted compared to WT mice, the fold change in mass compared to NC-fed controls was statistically indistinguishable from that in WT mice. Despite similar eWAT expansion, the number of macrophages and levels of pro-inflammatory cytokines in eWAT from 12/15LO KO mice were completely unchanged by HFD, and significantly different from the elevated levels we observed in HFD-fed WT mice. Our findings suggest that the proinflammatory effects of 12/15LO expression observed by Nunemaker, et al. after 8 and 24 weeks of HFD <xref ref-type="bibr" rid="pone.0007250-Nunemaker1">&#x0005b;30&#x0005d;</xref> in fact occur significantly earlier during the initial stages of HFD-induced insulin resistance (2&#x02013;4 weeks). Chakrabarti, et al. have recently demonstrated that 12/15LO is up-regulated in adipose tissue from high fat fed mice and that 12/15LO products induce inflammation and insulin resistance in 3T3-L1 adipoctyes <xref ref-type="bibr" rid="pone.0007250-Chakrabarti1">&#x0005b;46&#x0005d;</xref>. HFD-induced elevation of eWAT cytokine levels could originate from macrophages, adipocytes, endothelial cells and/or preadipocytes within adipose tissue. We speculate that pro-inflammatory macrophages and adipocytes are the most likely sources of elevated eWAT cytokines in high fat diet-fed WT mice.</p><p>We used a two- and four-week high fat feeding protocol because it significantly induces the phenotypes of insulin resistance and adipose tissue hypertrophy and inflammation in WT mice without causing the severe metabolic dysfunctions that manifest after longer high fat feeding <xref ref-type="bibr" rid="pone.0007250-Park1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Kraegen1">&#x0005b;8&#x0005d;</xref>. Mouse phenotypes induced by our high fat feeding protocol were similar to those observed in other time course studies of HFD-induced adipose tissue inflammation and insulin resistance <xref ref-type="bibr" rid="pone.0007250-Park1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007250-Nguyen1">&#x0005b;6&#x0005d;</xref>. Two-week high fat feeding induced hyperinsulinemia and severe hepatic and skeletal muscle insulin resistance in WT but not 12/15LO KO mice. 12/15LO KO mice exhibited significantly greater insulin-stimulated skeletal muscle Akt phosphorylation after HFD, compared to WT mice, corresponding to their greater insulin sensitivity. Given the cross-talk between adipose tissue, liver, and skeletal muscle that affects insulin sensitivity <xref ref-type="bibr" rid="pone.0007250-deLuca1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007250-Trayhurn1">&#x0005b;47&#x0005d;</xref>, protection from adipose tissue inflammation in the 12/15LO KO mice may be the primary site of action leading to protection from whole body insulin resistance.</p><p>In summary, we find that 12/15LO is a key modulator of the onset of high fat diet-induced insulin resistance in liver, muscle and adipose tissue. We provide evidence that the mechanism by which the 12/15LO KO mice are protected from the initial stages of HFD-induced insulin resistance involves suppression of adipose tissue pro-inflammatory macrophage infiltration and inflammatory cytokine elevation. 12/15LO is a key participant in the development of diet-induced insulin resistance and, thus, a viable therapeutic target for the treatment of human insulin resistance and type 2 diabetes.</p></sec></body><back><ack><p>We thank D.J. Young and the Flow Cytometry Resource at the Rebecca &#x00026; John Moores UCSD</p></ack><ref-list><title>References</title><ref id="pone.0007250-deLuca1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Luca</surname><given-names>C</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><year>2008</year><article-title>Inflammation and insulin resistance.</article-title><source>FEBS Lett</source><volume>582</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">18053812</pub-id></mixed-citation></ref><ref id="pone.0007250-Matsuzawa1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><year>2006</year><article-title>The metabolic syndrome and adipocytokines.</article-title><source>FEBS Lett</source><volume>580</volume><fpage>2917</fpage><lpage>2921</lpage><pub-id pub-id-type="pmid">16674947</pub-id></mixed-citation></ref><ref id="pone.0007250-Hotamisligil1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><year>2006</year><article-title>Inflammation and metabolic disorders.</article-title><source>Nature</source><volume>444</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">17167474</pub-id></mixed-citation></ref><ref id="pone.0007250-Park1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>YR</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Higashimori</surname><given-names>T</given-names></name><name><surname>Danton</surname><given-names>C</given-names></name><etal/></person-group><year>2005</year><article-title>Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice.</article-title><source>Diabetes</source><volume>54</volume><fpage>3530</fpage><lpage>3540</lpage><pub-id pub-id-type="pmid">16306372</pub-id></mixed-citation></ref><ref id="pone.0007250-Strissel1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strissel</surname><given-names>KJ</given-names></name><name><surname>Stancheva</surname><given-names>Z</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Perfield</surname><given-names>JW</given-names><suffix>2nd</suffix></name><name><surname>DeFuria</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Adipocyte death, adipose tissue remodeling, and obesity complications.</article-title><source>Diabetes</source><volume>56</volume><fpage>2910</fpage><lpage>2918</lpage><pub-id pub-id-type="pmid">17848624</pub-id></mixed-citation></ref><ref id="pone.0007250-Nguyen1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MT</given-names></name><name><surname>Favelyukis</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>AK</given-names></name><name><surname>Reichart</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>PA</given-names></name><etal/></person-group><year>2007</year><article-title>A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways.</article-title><source>J Biol Chem</source><volume>282</volume><fpage>35279</fpage><lpage>35292</lpage><pub-id pub-id-type="pmid">17916553</pub-id></mixed-citation></ref><ref id="pone.0007250-Kim1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Gimeno</surname><given-names>RE</given-names></name><name><surname>Higashimori</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><etal/></person-group><year>2004</year><article-title>Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle.</article-title><source>J Clin Invest</source><volume>113</volume><fpage>756</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">14991074</pub-id></mixed-citation></ref><ref id="pone.0007250-Kraegen1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraegen</surname><given-names>EW</given-names></name><name><surname>Clark</surname><given-names>PW</given-names></name><name><surname>Jenkins</surname><given-names>AB</given-names></name><name><surname>Daley</surname><given-names>EA</given-names></name><name><surname>Chisholm</surname><given-names>DJ</given-names></name><etal/></person-group><year>1991</year><article-title>Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats.</article-title><source>Diabetes</source><volume>40</volume><fpage>1397</fpage><lpage>1403</lpage><pub-id pub-id-type="pmid">1936601</pub-id></mixed-citation></ref><ref id="pone.0007250-Natarajan1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Gu</surname><given-names>JL</given-names></name><name><surname>Rossi</surname><given-names>J</given-names></name><name><surname>Gonzales</surname><given-names>N</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><etal/></person-group><year>1993</year><article-title>Elevated glucose and angiotensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells.</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><fpage>4947</fpage><lpage>4951</lpage><pub-id pub-id-type="pmid">8506339</pub-id></mixed-citation></ref><ref id="pone.0007250-YlaHerttuala1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name><name><surname>Rosenfeld</surname><given-names>ME</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Sigal</surname><given-names>E</given-names></name><etal/></person-group><year>1990</year><article-title>Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions.</article-title><source>Proc Natl Acad Sci U S A</source><volume>87</volume><fpage>6959</fpage><lpage>6963</lpage><pub-id pub-id-type="pmid">1698286</pub-id></mixed-citation></ref><ref id="pone.0007250-Scheidegger1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheidegger</surname><given-names>KJ</given-names></name><name><surname>Butler</surname><given-names>S</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><year>1997</year><article-title>Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway.</article-title><source>J Biol Chem</source><volume>272</volume><fpage>21609</fpage><lpage>21615</lpage><pub-id pub-id-type="pmid">9261183</pub-id></mixed-citation></ref><ref id="pone.0007250-Bolick1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolick</surname><given-names>DT</given-names></name><name><surname>Orr</surname><given-names>AW</given-names></name><name><surname>Whetzel</surname><given-names>A</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Hatley</surname><given-names>ME</given-names></name><etal/></person-group><year>2005</year><article-title>12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>25</volume><fpage>2301</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">16166569</pub-id></mixed-citation></ref><ref id="pone.0007250-Spanbroek1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanbroek</surname><given-names>R</given-names></name><name><surname>Hildner</surname><given-names>M</given-names></name><name><surname>Kohler</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>A</given-names></name><name><surname>Zintl</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>5152</fpage><lpage>5157</lpage><pub-id pub-id-type="pmid">11320251</pub-id></mixed-citation></ref><ref id="pone.0007250-Pidgeon1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pidgeon</surname><given-names>GP</given-names></name><name><surname>Lysaght</surname><given-names>J</given-names></name><name><surname>Krishnamoorthy</surname><given-names>S</given-names></name><name><surname>Reynolds</surname><given-names>JV</given-names></name><name><surname>O'Byrne</surname><given-names>K</given-names></name><etal/></person-group><year>2007</year><article-title>Lipoxygenase metabolism: roles in tumor progression and survival.</article-title><source>Cancer Metastasis Rev</source><volume>26</volume><fpage>503</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">17943411</pub-id></mixed-citation></ref><ref id="pone.0007250-Browse1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browse</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Jasmonate: an oxylipin signal with many roles in plants.</article-title><source>Vitam Horm</source><volume>72</volume><fpage>431</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">16492478</pub-id></mixed-citation></ref><ref id="pone.0007250-Delker1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delker</surname><given-names>C</given-names></name><name><surname>Stenzel</surname><given-names>I</given-names></name><name><surname>Hause</surname><given-names>B</given-names></name><name><surname>Miersch</surname><given-names>O</given-names></name><name><surname>Feussner</surname><given-names>I</given-names></name><etal/></person-group><year>2006</year><article-title>Jasmonate biosynthesis in Arabidopsis thaliana&#x02013;enzymes, products, regulation.</article-title><source>Plant Biol (Stuttg)</source><volume>8</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">16807821</pub-id></mixed-citation></ref><ref id="pone.0007250-Natarajan2"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Malik</surname><given-names>KU</given-names></name><name><surname>Fatima</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>BV</given-names></name></person-group><year>2001</year><article-title>Signaling mechanisms of nuclear factor-kappab-mediated activation of inflammatory genes by 13-hydroperoxyoctadecadienoic acid in cultured vascular smooth muscle cells.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>21</volume><fpage>1408</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">11557664</pub-id></mixed-citation></ref><ref id="pone.0007250-Miller1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>YI</given-names></name><name><surname>Viriyakosol</surname><given-names>S</given-names></name><name><surname>Binder</surname><given-names>CJ</given-names></name><name><surname>Feramisco</surname><given-names>JR</given-names></name><name><surname>Kirkland</surname><given-names>TN</given-names></name><etal/></person-group><year>2003</year><article-title>Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>1561</fpage><lpage>1568</lpage><pub-id pub-id-type="pmid">12424240</pub-id></mixed-citation></ref><ref id="pone.0007250-Miller2"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>YI</given-names></name><name><surname>Viriyakosol</surname><given-names>S</given-names></name><name><surname>Worrall</surname><given-names>DS</given-names></name><name><surname>Boullier</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>25</volume><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">15718493</pub-id></mixed-citation></ref><ref id="pone.0007250-Dwarakanath1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwarakanath</surname><given-names>RS</given-names></name><name><surname>Sahar</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Castanotto</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>JJ</given-names></name><etal/></person-group><year>2004</year><article-title>Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B).</article-title><source>J Mol Cell Cardiol</source><volume>36</volume><fpage>585</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">15081318</pub-id></mixed-citation></ref><ref id="pone.0007250-Li1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SL</given-names></name><name><surname>Dwarakanath</surname><given-names>RS</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs.</article-title><source>J Lipid Res</source><volume>46</volume><fpage>220</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">15576842</pub-id></mixed-citation></ref><ref id="pone.0007250-Dwarakanath2"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwarakanath</surname><given-names>RS</given-names></name><name><surname>Sahar</surname><given-names>S</given-names></name><name><surname>Lanting</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Stemerman</surname><given-names>MB</given-names></name><etal/></person-group><year>2008</year><article-title>Viral vector-mediated 12/15-lipoxygenase overexpression in vascular smooth muscle cells enhances inflammatory gene expression and migration.</article-title><source>J Vasc Res</source><volume>45</volume><fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">17943024</pub-id></mixed-citation></ref><ref id="pone.0007250-Reilly1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>KB</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Hatley</surname><given-names>ME</given-names></name><name><surname>Patricia</surname><given-names>MK</given-names></name><name><surname>Lannigan</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>9440</fpage><lpage>9450</lpage><pub-id pub-id-type="pmid">14676201</pub-id></mixed-citation></ref><ref id="pone.0007250-Wen1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Chakrabarti</surname><given-names>SK</given-names></name><name><surname>Aylor</surname><given-names>K</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages.</article-title><source>Endocrinology</source><volume>148</volume><fpage>1313</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">17170102</pub-id></mixed-citation></ref><ref id="pone.0007250-Natarajan3"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name></person-group><year>2004</year><article-title>Lipid inflammatory mediators in diabetic vascular disease.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>24</volume><fpage>1542</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">15166011</pub-id></mixed-citation></ref><ref id="pone.0007250-Wen2"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Vandenhoff</surname><given-names>GE</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name></person-group><year>2008</year><article-title>Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages.</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>294</volume><fpage>H1933</fpage><lpage>1938</lpage><pub-id pub-id-type="pmid">18296557</pub-id></mixed-citation></ref><ref id="pone.0007250-Persaud1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persaud</surname><given-names>SJ</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name><name><surname>Belin</surname><given-names>VD</given-names></name><name><surname>Kitsou-Mylona</surname><given-names>I</given-names></name><name><surname>Asare-Anane</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>The role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans.</article-title><source>Diabetes</source><volume>56</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">17192482</pub-id></mixed-citation></ref><ref id="pone.0007250-Chen1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>ZD</given-names></name><name><surname>Smith</surname><given-names>KM</given-names></name><name><surname>Carter</surname><given-names>JD</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name></person-group><year>2005</year><article-title>Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity.</article-title><source>Diabetologia</source><volume>48</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">15729574</pub-id></mixed-citation></ref><ref id="pone.0007250-McDuffie1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDuffie</surname><given-names>M</given-names></name><name><surname>Maybee</surname><given-names>NA</given-names></name><name><surname>Keller</surname><given-names>SR</given-names></name><name><surname>Stevens</surname><given-names>BK</given-names></name><name><surname>Garmey</surname><given-names>JC</given-names></name><etal/></person-group><year>2008</year><article-title>Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes.</article-title><source>Diabetes</source><volume>57</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">17940120</pub-id></mixed-citation></ref><ref id="pone.0007250-Nunemaker1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunemaker</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Pei</surname><given-names>H</given-names></name><name><surname>Kimble</surname><given-names>SD</given-names></name><name><surname>Keller</surname><given-names>SR</given-names></name><etal/></person-group><year>2008</year><article-title>12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet.</article-title><source>Am J Physiol Endocrinol Metab</source><volume>295</volume><fpage>E1065</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">18780776</pub-id></mixed-citation></ref><ref id="pone.0007250-Natarajan4"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Rosdahl</surname><given-names>J</given-names></name><name><surname>Gonzales</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>W</given-names></name></person-group><year>1997</year><article-title>Regulation of 12-lipoxygenase by cytokines in vascular smooth muscle cells.</article-title><source>Hypertension</source><volume>30</volume><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">9336387</pub-id></mixed-citation></ref><ref id="pone.0007250-Li2"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>SL</given-names></name><name><surname>Reddy</surname><given-names>MA</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group><year>2006</year><article-title>Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice.</article-title><source>Diabetes</source><volume>55</volume><fpage>2611</fpage><lpage>2619</lpage><pub-id pub-id-type="pmid">16936211</pub-id></mixed-citation></ref><ref id="pone.0007250-Cyrus1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyrus</surname><given-names>T</given-names></name><name><surname>Pratico</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><etal/></person-group><year>2001</year><article-title>Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice.</article-title><source>Circulation</source><volume>103</volume><fpage>2277</fpage><lpage>2282</lpage><pub-id pub-id-type="pmid">11342477</pub-id></mixed-citation></ref><ref id="pone.0007250-Zhao1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Funk</surname><given-names>CD</given-names></name></person-group><year>2004</year><article-title>Lipoxygenase pathways in atherogenesis.</article-title><source>Trends Cardiovasc Med</source><volume>14</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">15261891</pub-id></mixed-citation></ref><ref id="pone.0007250-Huo1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hyman</surname><given-names>MC</given-names></name><name><surname>Shashkin</surname><given-names>P</given-names></name><name><surname>Harry</surname><given-names>BL</given-names></name><etal/></person-group><year>2004</year><article-title>Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice.</article-title><source>Circulation</source><volume>110</volume><fpage>2024</fpage><lpage>2031</lpage><pub-id pub-id-type="pmid">15451785</pub-id></mixed-citation></ref><ref id="pone.0007250-Bolick2"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolick</surname><given-names>DT</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Whetzel</surname><given-names>A</given-names></name><name><surname>Fuller</surname><given-names>LC</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name></person-group><year>2006</year><article-title>12/15 lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NF-kappaB.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>26</volume><fpage>1260</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">16543492</pub-id></mixed-citation></ref><ref id="pone.0007250-Benz1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benz</surname><given-names>DJ</given-names></name><name><surname>Mol</surname><given-names>M</given-names></name><name><surname>Ezaki</surname><given-names>M</given-names></name><name><surname>Mori-Ito</surname><given-names>N</given-names></name><name><surname>Zelan</surname><given-names>I</given-names></name><etal/></person-group><year>1995</year><article-title>Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase.</article-title><source>J Biol Chem</source><volume>270</volume><fpage>5191</fpage><lpage>5197</lpage><pub-id pub-id-type="pmid">7890629</pub-id></mixed-citation></ref><ref id="pone.0007250-Ezaki1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezaki</surname><given-names>M</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name><name><surname>Steinberg</surname><given-names>D</given-names></name></person-group><year>1995</year><article-title>Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase.</article-title><source>J Lipid Res</source><volume>36</volume><fpage>1996</fpage><lpage>2004</lpage><pub-id pub-id-type="pmid">8558087</pub-id></mixed-citation></ref><ref id="pone.0007250-Miles1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>PD</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><year>2000</year><article-title>Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency.</article-title><source>J Clin Invest</source><volume>105</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">10675354</pub-id></mixed-citation></ref><ref id="pone.0007250-Kanda1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Tateya</surname><given-names>S</given-names></name><name><surname>Tamori</surname><given-names>Y</given-names></name><name><surname>Kotani</surname><given-names>K</given-names></name><name><surname>Hiasa</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.</article-title><source>J Clin Invest</source><volume>116</volume><fpage>1494</fpage><lpage>1505</lpage><pub-id pub-id-type="pmid">16691291</pub-id></mixed-citation></ref><ref id="pone.0007250-Kamei1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname><given-names>N</given-names></name><name><surname>Tobe</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Ohsugi</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>26602</fpage><lpage>26614</lpage><pub-id pub-id-type="pmid">16809344</pub-id></mixed-citation></ref><ref id="pone.0007250-Nomiyama1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomiyama</surname><given-names>T</given-names></name><name><surname>Perez-Tilve</surname><given-names>D</given-names></name><name><surname>Ogawa</surname><given-names>D</given-names></name><name><surname>Gizard</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><year>2007</year><article-title>Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice.</article-title><source>J Clin Invest</source><volume>117</volume><fpage>2877</fpage><lpage>2888</lpage><pub-id pub-id-type="pmid">17823662</pub-id></mixed-citation></ref><ref id="pone.0007250-Weisberg1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>SP</given-names></name><name><surname>McCann</surname><given-names>D</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Rosenbaum</surname><given-names>M</given-names></name><name><surname>Leibel</surname><given-names>RL</given-names></name><etal/></person-group><year>2003</year><article-title>Obesity is associated with macrophage accumulation in adipose tissue.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>1796</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">14679176</pub-id></mixed-citation></ref><ref id="pone.0007250-Patricia1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patricia</surname><given-names>MK</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Dooley</surname><given-names>AN</given-names></name><name><surname>Hernandez</surname><given-names>F</given-names></name><name><surname>Gu</surname><given-names>JL</given-names></name><etal/></person-group><year>2001</year><article-title>Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells.</article-title><source>Circ Res</source><volume>88</volume><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">11304487</pub-id></mixed-citation></ref><ref id="pone.0007250-Hatley1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatley</surname><given-names>ME</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Reilly</surname><given-names>KB</given-names></name><name><surname>Bolick</surname><given-names>DT</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name></person-group><year>2003</year><article-title>Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>25369</fpage><lpage>25375</lpage><pub-id pub-id-type="pmid">12734208</pub-id></mixed-citation></ref><ref id="pone.0007250-Chakrabarti1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>SK</given-names></name><name><surname>Cole</surname><given-names>BK</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Keller</surname><given-names>SR</given-names></name><name><surname>Nadler</surname><given-names>JL</given-names></name></person-group><year>2009</year><article-title>12/15-Lipoxygenase Products Induce Inflammation and Impair Insulin Signaling in 3T3-L1 Adipocytes.</article-title><source>Obesity (Silver Spring)</source></mixed-citation></ref><ref id="pone.0007250-Trayhurn1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trayhurn</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>IS</given-names></name></person-group><year>2005</year><article-title>Signalling role of adipose tissue: adipokines and inflammation in obesity.</article-title><source>Biochem Soc Trans</source><volume>33</volume><fpage>1078</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">16246049</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>Support for this research was provided, in part, by the University of California Discovery Program Project #bio03-10383 with matching grant funds provided by Pfizer, Inc (DDS, JMO). JC is an employee of Pfizer and participated as a collaborator in sample and data analysis for the project. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. JC participated as described above, no other person or entity of Pfizer, Inc. had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There are no other competing interests (as listed in the PLoS Competing Interests Policy) known to us.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Support for this research was provided by NIH grants K01-DK62025 (DDS) and R01HL081862 (DDS, PDM, YIM), American Heart Association grant 0530159N (YIM), and the University of California Discovery Program Project #bio03-10383 with matching grant funds provided by Pfizer, Inc. (JMO, DDS). JC is an employee of Pfizer and participated in sample and data analysis for the project. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. JC participated as described above, no other person or entity of Pfizer, Inc. had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>